论文部分内容阅读
本文讨论人的各种蛋白尿疾病时,可能引起肾小球屏障功能改变的机制。肾小球壁作为选择分子大小的滤过器动物和人的在体研究,有助于更多了解肾小球壁的滤过特性。在这些研究中,一种单一的大分子物质如右旋糖酐或聚乙烯基吡咯烷酮(Polyvinylpyrrolidone或者Povidone)常用作试验的溶质。这些物质的化学结构和分子形状是均一的,而它们的分子量和分子的大小则可在预定范围内随意改变。这种鉴别清除率的方法,其理论根据是:给予大分子的试验物质如右旋糖酐和参考溶质菊粉,二者均不被肾小管
This article discusses the mechanisms by which changes in the function of the glomerular barrier may be implicated in various human proteinuria diseases. Glomerular wall as a filter of choice for molecular size In-vivo studies in animals and humans will help to understand more about the filtration properties of the glomerular wall. In these studies, a single macromolecular substance such as dextran or polyvinylpyrrolidone or Povidone is often used as the solute for the test. The chemical structure and molecular shape of these substances are uniform, and their molecular weight and molecular size can be arbitrarily changed within a predetermined range. This method of identifying clearance rates is based on the rationale that test substances such as dextran and reference solutes are administered to macromolecules, both of which are not blocked by the renal tubules